NCT03025074 Blood Collection Biorepository for Liver Disease Research
| NCT ID | NCT03025074 |
| Status | Recruiting |
| Phase | — |
| Sponsor | State University of New York at Buffalo |
| Condition | Non-Alcoholic Steatohepatitis(NASH) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2013-07 |
| Primary Completion | 2099-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2013-07 with a primary completion date of 2099-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the liver.
Eligibility Criteria
Inclusion Criteria: * This protocol is to establish a biobank of blood samples from individuals with or without liver diseases including viral hepatitis, liver cancer, NASH, and negative control samples. * Children and teenagers will be special populations considered in this protocol. Exclusion Criteria: * Vulnerable populations such as adults unable to consent, infants, pregnant women or prisoners will not be considered for this research study.
Contact & Investigator
Andrew Talal, MD
PRINCIPAL INVESTIGATOR
University at Buffalo
Frequently Asked Questions
Who can join the NCT03025074 clinical trial?
This trial is open to participants of all sexes, aged 7 Years or older, studying Non-Alcoholic Steatohepatitis(NASH). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03025074 currently recruiting?
Yes, NCT03025074 is actively recruiting participants. Contact the research team at bmbauer@buffalo.edu for enrollment information.
Where is the NCT03025074 trial being conducted?
This trial is being conducted at Buffalo, United States.
Who is sponsoring the NCT03025074 clinical trial?
NCT03025074 is sponsored by State University of New York at Buffalo. The principal investigator is Andrew Talal, MD at University at Buffalo. The trial plans to enroll 1,000 participants.